Anti-anxiety effect of a novel 5-HT3 receptor antagonist N-(benzo[d]thiazol-2-yl)-3-ethoxyquinoxalin-2-carboxamide (6k) using battery tests for anxiety in mice

Indian Journal of Pharmacology

Volumn 46, Issue 1, 2014, Pages 100-104

  Kurhe, Yeshwant Vijay ^a   Radhakrishnan, Mahesh ^a   Thangaraj, Devadoss ^a   Gupta, Deepali ^a  

^a BIRLA INSTITUTE OF TECHNOLOGY AND SCIENCE   (India)

Author keywords

5 HT3 antagonist; Anxiety; Elevated plus maze; Hole board test; Open field test

Indexed keywords

ANXIOLYTIC AGENT; DIAZEPAM; N (BENZO[ D ]THIAZOL 2 YL) 3 ETHOXYQUINOXALIN 2 CARBOXAMIDE; SEROTONIN 3 ANTAGONIST; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANXIETY; ARTICLE; CONDITIONED TASTE AVERSION TEST; CONTROLLED STUDY; DRUG EFFECT; DRUG SYNTHESIS; ELEVATED PLUS MAZE TEST; HOLE BOARD TEST; INTERMETHOD COMPARISON; LIGHT-DARK TEST; MALE; MOUSE; NONHUMAN; OPEN FIELD TEST; REACTION TIME; REARING; TRANQUILIZING ACTIVITY;

5-HT3 ANTAGONIST; ANXIETY; ELEVATED PLUS MAZE; HOLE BOARD TEST; OPEN FIELD TEST;

ANIMALS; ANTI-ANXIETY AGENTS; ANXIETY; BEHAVIOR, ANIMAL; MALE; MICE; QUINOXALINES; RECEPTORS, SEROTONIN, 5-HT3; SEROTONIN ANTAGONISTS; THIAZOLES;

EID: 84893208187     PISSN: 02537613     EISSN: 19983751     Source Type: Journal    
DOI: 10.4103/0253-7613.125186     Document Type: Article

References (24)

1. Randall LO, Heise GA, Schallek W, Bagdon RE, Banziger RF, Boris A, et al. Pharmacological and clinical studies on Valium (T. M.), a new psychotherapeutic agent of the benzodiazepine class. Curr Ther Res 1961;3: 405-25.
2. Kessler RC, Ruscio AM, Shear K, Wittchen HU. Epidemiology of anxiety disorders. Curr Top Behav Neurosci 2010;2: 21-35.
3. Rickels K, Gargia-Espana F, Mandos LA, Case GW. Physician Withdrawal Checklist (PWC-20). J Clin Psychopharmacol 2008;28: 447-51.
4. Griffiths RR, Weerts EM. Benzodiazepine self-administration in humans and laboratory animals - implications for problems of long-term use and abuse. Psychopharmacology (Berl) 1997;134: 1-37.
5. Costall B, Naylor RJ. Anxiolytic potential of 5-HT3 antagonists. Pharmacol Toxicol 1992;70: 157-62.
6. Griebel G. 5-Hydroxytryptamine-interacting drugs in animal models of anxiety disorders: More than 30 years of research. Pharmacol Ther 1995;65: 319-95.
7. Kilpatrick GJ, Jones BJ, Tyers MB. Identification and distribution of 5-HT3 receptors in rat brain using radioligand binding. Nature 1987;330: 746-8.
8. Fozard JR. MDL 72222: A potent and highly selective antagonist at neuronal 5-hydroxytryptamine receptors. Naunyn Schmiedebergs Arch Pharmacol 1984;326: 36-44.
9. Kelley SP, Bratt AM, Hodge CW. Targeted gene deletion of the 5-HT3A receptor subunit produces an anxiolytic phenotype in mice. Eur J Pharmacol 2003;461: 19-25.
10. Costall B, Domeney AM, Gerrard PA, Kelly ME, Naylor RJ, Tyers MB. Effects of 5-HT receptor antagonists GR38032F, ICS205-930 and BRL43694 in test for anxiolytic activity. Br J Pharmacol 1988b;93:195.
11. Greist JH, Jefferson JW. Pharmacotherapy for obsessive-compulsive disorder. Br J Psychiatry Suppl 1998;35: 64-70.
12. Lecrubier Y, Puech AJ, Azcona A, Bailey PE, Lataste X. A randomized doubleblind placebo-controlled study of tropisetron in the treatment of outpatients with generalized anxiety disorder. Psychopharmacology 1993;112: 129-33.
13. Rajkumar R, Mahesh R. The auspicious role of 5-HT3 receptors in depression: A probable neuronal target? J Psychopharmacol 2010;24: 455-69.
14. Mahesh R, Devadoss T, Pandey DK, Yadav SK. Quinoxalin-2-carboxamides: Synthesis and pharmacological evaluation as serotonin type-3 (5-HT3) receptor antagonists. J Enzyme Inhib Med Chem 2011;26: 610-5.
15. Rodgers RJ, Dalvi A. Anxiety, defence and the elevated plus-maze. Neurosci Biobehav Rev 1997;21: 801-10.
16. Prut L, Belzung C. The open field as a paradigm to measure the effects of drugs on anxiety-like behaviors: A review. Eur J Pharmacol 2003;463: 3-33.
17. Crawley J, Goodwin FK. Preliminary report of a simple animal behaviour model for the anxiolytic effects of benzodiazepines. Pharmacol Biochem Behav 1980;13: 167-70.
18. Nolan NA, Parkes MW. The effects of benzodiazepines on the behavior of mice on a hole board. Psychopharmacologia 1973;29: 277-88.
19. Weiss SM, Wadsworth G, Fletcher A, Dourish CT. Utility of ethological analysis to overcome locomotor confounds in elevated plus-maze of anxiety. Neurosci Behav Rev 1998;23: 265-71.
20. Dawson GR, Tricklebank MD. Use of the elevated plus-maze in the search for novel anxiolytic agents. Trends Pharmacol Sci 1995;16: 33-6.
21. Imaizumi M, Suzuki T, Machida H, Onodera K. A fully automated apparatus for a light/dark test measuring anxiolytic or anxiogenic effects of drugs in mice. Nihon Shinkei Seishin Yakurigaku Zasshi 1994;14: 83-91.
22. Takeda H, Tsuji M, Matsumiya T. Changes in head-dipping behavior in the holeboard test reflect the anxiogenic and/or anxiolytic state in mice. Eur J Pharmacol 1998;350: 21-9.
23. Greenshaw AJ. Behavioral pharmacology of 5-HT, receptor antagonists: A critical update on therapeutic potential. Trends Pharmacol Sci 1992;14: 265-70.
24. Kilpatrick GJ, Butler A, Ireland SJ, Michel AD, Tyers MB. Affinities of 5-HT uptake inhibitors for 5-HT, receptors in both binding and functional studies. Br J Pharmacol 1989;98:859.